CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2023. The put-call ratio across all filers is 0.94 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,101 | -2.0% | 29,737 | +11.0% | 0.00% | 0.0% |
| Q1 2024 | $1,124 | +28.2% | 26,790 | +21.1% | 0.00% | 0.0% |
| Q4 2023 | $877 | +34.1% | 22,116 | -7.0% | 0.00% | 0.0% |
| Q3 2023 | $654 | -16.0% | 23,780 | +3.6% | 0.00% | 0.0% |
| Q2 2023 | $779 | -21.4% | 22,959 | -16.6% | 0.00% | 0.0% |
| Q1 2023 | $991 | -32.0% | 27,545 | -15.7% | 0.00% | -50.0% |
| Q4 2022 | $1,457 | -99.8% | 32,679 | -0.1% | 0.00% | +100.0% |
| Q3 2022 | $920,000 | +4.7% | 32,719 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $879,000 | -21.1% | 32,622 | -0.3% | 0.00% | 0.0% |
| Q1 2022 | $1,114,000 | -11.8% | 32,705 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $1,263,000 | -23.4% | 32,681 | +7.1% | 0.00% | -50.0% |
| Q3 2021 | $1,648,000 | +46.6% | 30,516 | -9.2% | 0.00% | +100.0% |
| Q2 2021 | $1,124,000 | – | 33,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,388,967 | $125,425,669 | 9.68% |
| 5AM Venture Management, LLC | 497,270 | $18,403,963 | 4.12% |
| COMMODORE CAPITAL LP | 1,425,000 | $52,739,250 | 3.60% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 374,910 | $13,875,419 | 3.27% |
| TSP Capital Management Group, LLC | 249,220 | $9,223,635 | 2.89% |
| Eventide Asset Management | 3,327,132 | $123,137,155 | 2.11% |
| Affinity Asset Advisors, LLC | 475,400 | $17,594,554 | 2.03% |
| Novo Holdings A/S | 850,000 | $31,458,500 | 1.83% |
| Bellevue Group AG | 2,971,615 | $109,979,471 | 1.79% |
| Redmile Group, LLC | 718,723 | $26,599,938 | 1.61% |